Sunday, December 21, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Upgrades Lam Research Price Target to 912

Elaine Mendonca by Elaine Mendonca
January 25, 2024
in Breaking News
0
Biotechnology Stock Bull Market
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

On January 25, 2024, Toshiya Hari, an analyst at Goldman Sachs, expressed his positive stance on Lam Research (NASDAQ:LRCX) by maintaining a Buy rating and revising the price target to $912, up from $700. This upward adjustment in the price target indicates a favorable outlook for the company’s stock. Notably, other analysts also share an optimistic view, with an average target price of $747.09 and a high price target of $885. These figures further reinforce the market’s confidence in Lam Research’s potential for strong future performance.

Lam Research Corporation (LRCX) Shows Strong Performance in Stock Market with Positive Price Momentum

On January 25, 2024, Lam Research Corporation (LRCX) showcased a strong performance in the stock market, indicating positive price momentum. LRCX was trading near the top of its 52-week range and above its 200-day simple moving average, suggesting a bullish trend for the company.

The price of LRCX shares experienced a notable increase of $17.44 since the market last closed, representing a rise of 2.06%. LRCX closed the day at $865.60, reflecting the upward movement in its stock price.

However, it is important to note that the stock experienced a drop of $9.60 in after-hours trading. After-hours trading refers to the buying and selling of stocks outside the regular trading hours of the stock market.

Despite the drop in after-hours trading, the overall performance of LRCX on January 25, 2024, remains positive. The stock displayed strong price momentum, trading near its 52-week high and above its 200-day simple moving average. These factors indicate a favorable market sentiment towards LRCX and suggest that investors have confidence in the company’s future growth potential.

Investors and market participants should closely monitor the performance of LRCX in the coming days to assess whether the after-hours drop has any significant impact on the stock’s overall trajectory. It is important to consider other factors such as market trends, company news, and industry developments to make informed investment decisions.

Stable Revenue and Positive Growth: A Look at Lam Research Corporations Performance in Q2 2024

On January 25, 2024, Lam Research Corporation (LRCX) showcased a stable performance in terms of total revenue, with a slight increase in net income and earnings per share (EPS) since the previous quarter. According to data obtained from CNN Money, LRCX reported a total revenue of $17.43 billion over the past year, with $3.76 billion generated in the second quarter alone. This indicates that the company’s revenue has remained flat since the previous year. However, there has been a notable increase of 7.93% in revenue since the last quarter. In terms of net income, LRCX reported a figure of $4.51 billion over the past year, with $954.27 million generated in the second quarter. Similar to total revenue, net income has remained flat since the previous year. However, there has been a growth of 7.54% in net income since the last quarter. Furthermore, LRCX’s EPS, a key metric used by investors to evaluate a company’s profitability, has also shown positive growth. The company reported an EPS of $33.21 over the past year, with $7.22 generated in the second quarter. Similar to net income and total revenue, EPS has remained flat since the previous year. However, there has been an increase of 8.35% in EPS since the last quarter. In conclusion, LRCX’s stock performance on January 25, 2024, showcased stable total revenue, with a slight increase in net income and EPS since the previous quarter. The company’s ability to maintain its revenue and generate consistent sales is a positive indicator of its market position and financial stability. The growth in net income and EPS indicates LRCX’s ability to improve profitability and generate higher returns for investors. Overall, these figures suggest that LRCX is on a positive trajectory and may present a promising investment opportunity.

Tags: LRCX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Alternative Energy Stock Market Today

Analyst Upgrades YPF to Buy Rating Predicts Potential Growth and Profitability

Levi Strauss Co Seeks 10Year Extension for Levis Stadium Naming Rights

Transportation Stock Bull Market

Rail Visions Main Line System Achieves EU Railway Standards Approval and Certifications

Recommended

JD.com Stock

Pivotal Week Ahead for JD.com as Major European Acquisition and EV Launch Converge

2 months ago
Snowflake Stock

Snowflake Faces Investor Confidence Test After Executive’s Rogue Forecast

2 months ago
Fiserv Stock

Fiserv’s Strategic Expansion Meets Legal Scrutiny

3 months ago
Does_Walmart_Take_Google_Pay

Does Walmart Take Google Pay? Exploring Walmart’s Exclusive Payment Solution

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

Strategy Inc. Faces a Critical Index Classification Decision

DeFi Technologies Broadens Global Reach with New Listings and Products

Barrick Gold Secures Key Resolution in Mali, Paving Way for Mine Restart

Analyst Upgrade Sends Red Cat Shares Soaring

A Billion-Dollar Vote of Confidence for Standard Lithium

Trending

Tesla Stock
Automotive & E-Mobility

Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push

by Dieter Jaworski
December 21, 2025
0

Tesla shares are trading near their 52-week high as the company approaches a pivotal week, fueled by...

Wolfspeed Stock

Wolfspeed Secures Financial and Strategic Milestones

December 21, 2025
Textron Stock

Textron Stock Approaches Annual Peak Amid Strategic Wins

December 21, 2025
Intellia Therapeutics Stock

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

December 21, 2025
Strategy Stock

Strategy Inc. Faces a Critical Index Classification Decision

December 21, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push
  • Wolfspeed Secures Financial and Strategic Milestones
  • Textron Stock Approaches Annual Peak Amid Strategic Wins

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com